Browsing by Author "Zuo, Peijun"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    NMDA Inhibitors: A Potential Contrivance to Assist in Management of Alzheimer’s Disease
    (Bentham Science Publishers B.V., 2023-03) Painuli, Sakshi; Semwal, Prabhakar; Zam, Wissam; Taheri, Yasaman; Ezzat, Shahira M; Zuo, Peijun; Li, Liping; Kumar, Dileep; Sharifi-Rad, Javad; Cruz-Martins, Natália
    Alzheimer’s disease (AD) is an increasingly common neurodegenerative disease that at- tracts the attention of researchers and medical community in order to develop new, safe and more effective drugs. Currently available drugs could only slow the AD progression and relieve the symptoms, in addition to being linked to moderate-to-severe side effects. N-methyl D-aspartate (NMDA) receptors antagonists were reported to have the ability to block the glutamate-mediated excitotoxic activity being good therapeutic targets for several neurodegenerative diseases, includ- ing AD. Based on data obtained so far, this review provides an overview over the use of NMDA antagonists for AD treatment, starting with a key emphasis on present features and future aspects regarding the use of NMDA antagonists for AD, and lastly a key focus is also given on its use in precision medicine.
  • Thumbnail Image
    Item
    NMDA Inhibitors: A Potential Contrivance to Assist in Management of Alzheimer Disease
    (Bentham Science Publishers, 2022-04) Painuli, Sakshi; Semwal, Prabhakar; Zam, Wissam; Taheri, Yasaman; Ezzat, Shahira M; Zuo, Peijun; Li, Liping; Kumar, Dileep; Sharifi-Rad, Javad; Cruz- Martins, Natália
    Alzheimer disease (AD) is an increasingly common neurodegenerative disease, and therefore researchers and medical community are devoting a key attention in searching new, safer and more effective drugs than the currently available ones. Currently available drugs are not an effective treatment to the disease, they only slow the AD progression and act in symptoms relief, despite being linked to moderate-to-severe side effects. N-methyl D-aspartate (NMDA) receptors antagonists and cholinesterase inhibitors, and combination therapy, are the most often used therapeutic regimens in AD patients. In particular, NMDA receptors have being target of an increasing attention while good therapeutic targets for several neurodegenerative diseases, including AD, due to their ability to block the glutamate-mediated excitotoxic activity. Based on data obtained so far, this review provides an overview on the use of NMDA antagonists for AD treatment, starting with a key emphasis on present features and future aspects on the use of NMDA antagonists for AD, and lastly a key focus is also given on its use for precision medicine.